# NIH Funds VeraMorph Fulvestrant Research

The National Institutes of Health awarded VeraMorph LLC a **$2.1 million SBIR Phase II grant** to complete IND-enabling and preclinical proof-of-concept studies for its oral fulvestrant product. Reported October 15, 2026, the award supports planned clinical testing in 2027 and a planned NDA submission in 2029; VeraMorph also reported favorable FDA feedback on its proposed clinical strategy. This is a funded biotech R&D effort, not an open solicitation, but it signals development work that may be relevant to specialized research and clinical-development contractors.

- The grant recipient is VeraMorph; firms providing relevant preclinical, IND-enabling, or drug-development services can evaluate whether to pursue direct engagement or subcontracting opportunities. No solicitation or specific procurement timeline is identified.
- The company’s stated plans for clinical testing in 2027 and an NDA submission in 2029 provide context for the anticipated development sequence, but are company plans rather than announced procurement deadlines.
- The award illustrates NIH SBIR funding supporting early-stage therapeutic development; contractors should distinguish this grant-funded activity from an agency contract competition when assessing business opportunities.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** October 15, 2026

### Government Entities
- National Institutes of Health (NIH)
- Food and Drug Administration (FDA)

### Vendors
- VeraMorph LLC (SBIR Phase II grant recipient)

### Key Quotes
> Our recent engagement with the FDA confirms the enthusiasm for novel oral SERDs within the breast cancer community and the long history of fulvestrant provides confidence in the potential for a superior therapy among this patient population.
> — Daniel O’Connor, Chief Executive Officer of VeraMorph

### Sources
- [VeraMorph Completes Positive Pre-IND Meeting on Oral Fulvestrant Product, Receives NIH SBIR Phase II Grant, and Names New CEO](https://www.businesswire.com/news/home/20261014279184/en/VeraMorph-Completes-Positive-Pre-IND-Meeting-on-Oral-Fulvestrant-Product-Receives-NIH-SBIR-Phase-II-Grant-and-Names-New-CEO) - Business Wire